IN THE SPOTLIGHT

Rybrevant Combo Approved as First-Line Tx for NSCLC With EGFR Exon 20 Insertion Mutations

Rybrevant Combo Approved as First-Line Tx for NSCLC With EGFR Exon 20 Insertion Mutations

FDA Approves Amivantamab First-line Indication for NSCLC

FDA Approves Amivantamab First-line Indication for NSCLC

Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC

Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC

FDA OKs Amivantamab as First-Line Lung Cancer Treatment

FDA OKs Amivantamab as First-Line Lung Cancer Treatment

AstraZeneca touts ‘overwhelming’ Tagrisso win among 3 lung cancer advancements

AstraZeneca touts ‘overwhelming’ Tagrisso win among 3 lung cancer advancements

AstraZeneca gets new Tagrisso OK as drug succeeds in another trial

AstraZeneca gets new Tagrisso OK as drug succeeds in another trial

Trial for AstraZeneca’s lung cancer drug Tagrisso points to increased survival rate

Trial for AstraZeneca’s lung cancer drug Tagrisso points to increased survival rate

FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer

FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer

AstraZeneca’s Tagrisso With Chemotherapy Gets FDA Approval for EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca’s Tagrisso With Chemotherapy Gets FDA Approval for EGFR-Mutated Non-Small Cell Lung Cancer

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC